Technical Analysis for ALVR - AlloVir, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Up |
| Historical ALVR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 3.49% | |
| NR7 | Range Contraction | 1.49% | |
| NR7-2 | Range Contraction | 1.49% | |
| Wide Bands | Range Expansion | 1.49% | |
| 20 DMA Resistance | Bearish | -3.50% | |
| NR7 | Range Contraction | -3.50% | |
| Wide Bands | Range Expansion | -3.50% | |
| Inside Day | Range Contraction | -0.78% | |
| Wide Bands | Range Expansion | -0.78% | |
| Wide Bands | Range Expansion | 2.24% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Rose Above 10 DMA | 32 minutes ago |
| 60 Minute Opening Range Breakout | about 1 hour ago |
| Rose Above Previous Day's High | about 1 hour ago |
| 10 DMA Resistance | about 1 hour ago |
| Up 3% | about 1 hour ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Immune System Stem Cells Gene Therapy Manufacturing Process Proprietary Technology Cell Biology Viruses Cell Therapy Immunity Viral Disease Virus Viral Diseases Zoonoses
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Immune System Stem Cells Gene Therapy Manufacturing Process Proprietary Technology Cell Biology Viruses Cell Therapy Immunity Viral Disease Virus Viral Diseases Zoonoses
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 48.96 |
| 52 Week Low | 18.15 |
| Average Volume | 422,496 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 32.82 |
| 20-Day Moving Average | 24.15 |
| 10-Day Moving Average | 23.21 |
| Average True Range | 2.13 |
| ADX | 48.18 |
| +DI | 10.61 |
| -DI | 29.44 |
| Chandelier Exit (Long, 3 ATRs ) | 26.00 |
| Chandelier Exit (Short, 3 ATRs ) | 26.50 |
| Upper Bollinger Band | 28.73 |
| Lower Bollinger Band | 19.56 |
| Percent B (%b) | 0.35 |
| BandWidth | 38.00 |
| MACD Line | -2.62 |
| MACD Signal Line | -3.19 |
| MACD Histogram | 0.5671 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.45 | ||||
| Resistance 3 (R3) | 25.39 | 24.44 | 25.00 | ||
| Resistance 2 (R2) | 24.44 | 23.76 | 24.47 | 24.85 | |
| Resistance 1 (R1) | 23.60 | 23.33 | 23.13 | 23.66 | 24.70 |
| Pivot Point | 22.65 | 22.65 | 22.41 | 22.68 | 22.65 |
| Support 1 (S1) | 21.81 | 21.97 | 21.34 | 21.87 | 20.82 |
| Support 2 (S2) | 20.86 | 21.54 | 20.89 | 20.67 | |
| Support 3 (S3) | 20.02 | 20.86 | 20.52 | ||
| Support 4 (S4) | 20.08 |
